Export

EN
FR
Cisplatin
Essential medicine status
Section:
8. Immunomodulators and antineoplastics 8.2. Antineoplastics and supportive medicines 8.2.1. Cytotoxic medicines
ATC codes: L01XA01
EMLc
Indication
Malignant neoplasms of nasopharynx ICD11 code: 2C3B.Z
INN
Cisplatin
Medicine type
Chemical agent
List type
Core (EML)
(EMLc)
Formulations
Parenteral > General injections > IV: 50 mg per 50 mL ; 100 mg per 100 mL ; 10 mg per 10 mL ; 20 mg per 20 mL
EML status history
First added in 1984 (TRS 722)
Changed in 2015 (TRS 994)
Changed in 2019 (TRS 1021)
Changed in 2021 (TRS 1035)
Sex
All
Age
Also recommended for children
Therapeutic alternatives
The recommendation is for this specific medicine
Patent information
Patents have expired in most jurisdictions
Tags
Wikipedia
Cisplatin
DrugBank
Cisplatin
Summary of evidence and Expert Committee recommendations
The Expert Committee recommended the addition of new strength formulations of cisplatin IV injection (10 mg/10 mL and 20 mg/20 mL) to the EML and EMLc.